LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.25 -0.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.24

Massimo

31.27

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.052 49.701
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+5.89% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	281M 3.8B
Apertura precedente	31.35
Chiusura precedente	31.25

Notizie sul Sentiment di mercato

By Acuity

50%

159 / 345 Classifica in Healthcare

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mag 2026, 08:24 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mag 2026, 21:22 UTC

Utili

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mag 2026, 20:50 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:01 UTC

Discorsi di Mercato

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mag 2026, 14:43 UTC

Discorsi di Mercato

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mag 2026, 14:15 UTC

Discorsi di Mercato

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mag 2026, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

25 mag 2026, 12:58 UTC

Discorsi di Mercato

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mag 2026, 12:56 UTC

Discorsi di Mercato

Utili

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mag 2026, 12:34 UTC

Discorsi di Mercato

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mag 2026, 12:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 mag 2026, 11:00 UTC

Discorsi di Mercato

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mag 2026, 10:19 UTC

Discorsi di Mercato

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mag 2026, 10:05 UTC

Utili

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mag 2026, 10:04 UTC

Utili

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mag 2026, 10:03 UTC

Utili

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mag 2026, 10:02 UTC

Utili

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mag 2026, 10:01 UTC

Utili

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mag 2026, 10:00 UTC

Utili

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q EPS MYR0.1883

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Rev MYR17.1B

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Net MYR1.1B

25 mag 2026, 09:38 UTC

Discorsi di Mercato

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mag 2026, 08:55 UTC

Discorsi di Mercato

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

5.89% in crescita

Previsioni per 12 mesi

Media 33.1 USD 5.89%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

159 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.